【摘要】 目的:探讨进展期乳腺癌新辅助化疗的临床意义。方法:2000年1月至2005年6月应用CAF方案对72例Ⅲ期乳腺癌患者进行新辅助化疗。环磷酰胺(CTX)500mg/m2,d1,阿霉素(ADM)50mg/m2,d1,d8;氟尿嘧啶(5 Fu)500mg/m2,d1,21d为1个周期,所有患者完成3个周期新辅助化疗后评价疗效。结果:29例(40.3%)降低了临床分期;3例(4.2%)获得完全缓解(CR),30例(44.4%)部分缓解(PR),全组无疾病进展(PD)者,总有效率(CR+PR)为45.8%(33/86)。新辅助化疗3个周期后有21例(28.9%)未触及肿大淋巴结,腋窝淋巴结总有效率为70.8%(51/72)。副反应为白细胞下降、恶心呕吐和脱发等,患者均可耐受。结论:进展期乳腺癌新辅助化疗对原发肿瘤和腋窝淋巴结均有较好疗效,不良反应可耐受,值得推广。更多还原

【Abstract】 Objective: To evaluate the clinical significance of CAF regimen as neoadjuvant chemotherapy for stage Ⅲ breast cancer.Method: Seventy two patients with stage Ⅲbreast cancer were treated with CAF regimen for 3 treatment cycles with each lasting for 21d.According to the effect standard and toxic grading standard suggested byWHO,the efficacy and safety were evaluated.The patients received cyclophosphamide(CTX)500mg/m~2 on day1,ADM50mg/m~2 on day 1,and 8,and 5 fluorouracil(5 Fu) 500mg/m~2 on day 1.Result: The cancer degraded in 29(40.3%%) patients and the over all responserate(RR) of the primary tumor was 45.8%(33/86).3 cases had complete response(CR),30 cases partial response(PR) and no disease progressive(PD) case.For axillary lymphnodes,the over all responserate(RR) was 70.8%(51/72).For clinically palpable axillary lymphnodes which had been found in 72 patients before treatment,28.9%(21/72)became inpalpable.The major toxicity included leukopenia,gastroenteric reactions and alopecia.Conclusion: Neoadjuvant chemotherapy with CAF regimen for stage Ⅲ breast cancer is effective and tolerable and therefore,is warranted for wid euse.更多还原